StockNews.AI
CLGN
StockNews.AI
14 days

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS

1. CollPlant to report Q2 financial results on August 20, 2025. 2. Their rhCollagen technology focuses on 3D tissue bioprinting and aesthetics. 3. Partnership with Allergan enhances market presence in dermal fillers. 4. Innovations could lead to broader adoption in regenerative medicine. 5. Potential market shifts before financial reporting may impact stock performance.

4m saved
Insight
Article

FAQ

Why Bullish?

CollPlant's innovative approach and partnerships position it well for growth, similar to growth seen in other biotech stocks following successful partnerships, like Amgen and Pfizer.

How important is it?

The announcement of financial results and ongoing partnerships signifies potential growth, which is crucial for investors' short-term strategies.

Why Short Term?

Upcoming Q2 financial results will provide immediate insights into performance, influencing investor sentiment quickly.

Related Companies

ABBVAMGN
, /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the second quarter on Wednesday, August 20, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. For more information about CollPlant, visit http://www.collplant.com. Contacts: CollPlant:Eran RotemDeputy CEO & CFOTel: +972-73-2325600Email: [email protected]  Investors:Daniel FerryManaging DirectorLifeSci Advisors, LLC[email protected]  Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg SOURCE CollPlant WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News